According to the Red Star Capital Bureau, the stock price of weight loss drug giant LY. US fell at the beginning of trading on December 11th local time, with a drop of over 5% during the trading session. The subsequent decline has eased. As of the close, it fell 2.34% to $584.04 per share, with a total market value of $554.4 billion.
On the news side, according to a report by Caixin, a study published in the Journal of the American Medical Association showed that after using Eli Lilly's weight loss drug Zepbound for about eight months and discontinuing administration, the weight of the subjects slowly rebounded, and the weight lost increased by half again one year later.
Specifically, 670 patients lost 20.9% of their weight after approximately 8 months of using Zepbound. Afterwards, half of the patients continued to receive Zepbound for another year, while the other half received placebo.
The data shows that patients who continued to receive Zepbound had an average weight loss of 5.5%, while the other half of patients who received placebo had an average weight gain of 14%.
Red Star Capital Bureau noted that on November 9, Lilly announced that the company's tirzepatide injection (trade name: Zepbound) was approved by the U.S. Food and Drug Administration (FDA) and was applicable to long-term weight management of overweight adults who were obese or had at least one complication (such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease).
The main ingredient of Zepbound is Tilpatide, which, according to Lilly, is the first and currently the only approved drug that can activate two types of intestinal trypsin receptors (GIP and GLP-1), targeting the root cause of weight gain. According to reports, Novo Nordisk's (NVO.US) semaglutide only targets GLP-1.